Adenosine: Nursing Drug Guide, Rapid IV Push & NCLEX Review

Adenosine is supplied generically and under trade names depending on region and indication (arrhythmia bolus vs pharmacologic stress imaging uses different products—verify the vial and protocol).

Common U.S. brand names (bolus antiarrhythmic): Adenocard. Related agents (not interchangeable): regadenoson and other adenosine A_2A agonists are used for myocardial perfusion imaging with different dosing (continuous infusion)—do not substitute for PSVT bolus orders.

IV adenosine is indicated to convert paroxysmal supraventricular tachycardia (PSVT) to normal sinus rhythm, including PSVT with accessory bypass tracts (Wolff-Parkinson-White pattern). When clinically advisable, attempt vagal maneuvers (e.g., Valsalva) before adenosine. It is an emergency rhythm drug—not routine analgesia or sedation.

↔On a small screen, swipe or scroll sideways to see the full table.

Adenosine slows conduction through the AV node, interrupts reentry pathways, and can restore sinus rhythm in PSVT. It is antagonized by methylxanthines (theophylline, caffeine) and potentiated by dipyridamole. It is not blocked by atropine. After IV bolus, adenosine is rapidly cleared by cellular uptake (especially erythrocytes and endothelium); hepatic or renal failure is not expected to alter bolus effectiveness because activation does not depend on those organs.

For rapid bolus intravenous use only. Doses greater than 12 mg are not recommended for adult and pediatric patients per labeling.

Renal / hepatic impairment: Not specified in the reviewed prescribing information for bolus dose adjustment (drug does not require hepatic or renal activation).

Missed dose: Not applicable—adenosine is given as single emergent boluses during PSVT, not on a standing schedule.

Pretreatment checks

• Confirm narrow-complex regular tachycardia consistent with PSVT; obtain 12-lead ECG when feasible and compare to prior tracings
• Large-bore proximal IV access, prefilled saline flush (20 mL), continuous cardiac monitor, and emergency cart at bedside
• Review history of asthma, COPD/bronchitis, digoxin, verapamil, carbamazepine, and methylxanthine use; perform medication reconciliation

Contraindications

• Second- or third-degree AV block (except functioning artificial pacemaker)
• Sick sinus syndrome or symptomatic bradycardia (except functioning pacemaker)
• Known hypersensitivity to adenosine

Asthma / bronchospasm: Labeling states adenosine should be avoided in bronchoconstriction or bronchospasm (e.g., asthma) and used with caution in other obstructive lung disease; discontinue if severe respiratory difficulty develops.

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Rapid bolus IV only—never IM, SC, or continuous infusion for PSVT (stress-test regimens use different products and rates).

• Administer directly into a vein or into the most proximal port of an IV line
• Push 6 mg (2 mL of 3 mg/mL) over 1–2 seconds, then immediately flush with rapid saline (typically 10–20 mL) using a two-syringe or push-flush technique
• Second clinician records rhythm on monitor; time bolus and note response at 1–2 minutes before repeat 12 mg dose

• Termination of PSVT with return to sinus rhythm—often within 1–2 minutes of bolus (labeling clinical trials: ~60% converted after 6 mg sequence, ~92% after 12 mg in studied populations)
• Brief period of asystole, junctional rhythm, or ventricular ectopy on monitor during conversion—usually self-limited
• Transient flushing, chest pressure, dyspnea, or dizziness lasting seconds to a few minutes

Most effects are short-lived, but some require immediate escalation beyond “wait and see.”

• Prolonged asystole or high-level AV block after a dose—do not give additional adenosine; activate emergency response and treat per ACLS/pacing protocol
• Ventricular fibrillation or sustained ventricular tachycardia—defibrillation and advanced life support per protocol
• Severe wheezing, bronchospasm, or respiratory distress—stop drug, bronchodilator therapy and escalation per prescriber
• PSVT persists after maximum labeled bolus doses—notify prescriber for alternate cardioversion (e.g., synchronized cardioversion or other antiarrhythmics per protocol)
• Seizure or loss of consciousness (post-marketing reports)—ABC support and urgent evaluation

↔On a small screen, swipe or scroll sideways to see the full table.

Because the half-life is less than 10 seconds, toxic effects are generally rapidly self-limiting unless prolonged high-level block or arrhythmia occurs.

Management

• Individualize treatment to the specific prolonged effect (e.g., pacing for symptomatic bradycardia, ACLS for VF)
• Antidote / antagonist: Methylxanthines such as caffeine or theophylline are competitive antagonists per overdosage section—administration per toxicology/prescriber guidance when prolonged effects persist

There is no routine “antidote” syringe at bedside; prevention (technique, contraindication screening) is the primary safety strategy.

• Adenosine vs regadenosin / Lexiscan—stress imaging agents are not PSVT bolus doses
• 6 mg vs 12 mg prefilled syringes—read vial volume (2 mL vs 4 mL at 3 mg/mL) before administration
• Bolus vs infusion—some adenosine products are labeled for pharmacologic stress testing with continuous infusion; never infuse PSVT orders on a pump
• “Slow push” habit—most dangerous LASA-like practice is administering like a standard IV medication
• Distal IV port—same drug name, wrong delivery site prevents therapeutic effect

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Continuous cardiac rhythm and blood pressure during and for several minutes after each bolus
• Respiratory status and SpO₂—especially in patients with reactive airway disease or COPD
• Symptoms: palpitations, chest discomfort, dyspnea, neurologic changes

Document

• Pre-bolus rhythm, dose (mg), push duration, flush volume, post-bolus rhythm at 1–2 minutes, and repeat doses
• Patient symptoms during pause, interventions for prolonged pause or bronchospasm, and prescriber notifications
• Vagal maneuvers attempted and final rhythm outcome

• “You may feel a very brief pause in your heartbeat, flushing, chest tightness, or shortness of breath—that often lasts only seconds.”
• Report sudden severe breathing difficulty, fainting, or chest pain that does not resolve quickly
• After conversion, discuss triggers for heart arrhythmia follow-up and when to seek emergency care for recurrent palpitations
• Continue prescribed cardiac medications unless the prescriber changes the plan—do not stop rate-control or antiarrhythmic drugs without instructions
• Avoid excessive caffeine if repeat adenosine may be needed and prescriber advises methylxanthine interaction concern

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

↔On a small screen, swipe or scroll sideways to see the full table.

This NCLEX-style clinical judgment practice set for adenosine uses a tabbed emergency case (MAR, rhythm strips/labs, vitals, nursing notes), then priority action, cue recognition, post-bolus trend interpretation, matrix urgency sorting, repeat-dose judgment, and administration cloze—recognise cues → analyse → prioritise → act → evaluate outcomes (conversion vs persistent PSVT vs prolonged pause).

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.